GB9710807D0 - Nucleic acid binding proteins - Google Patents

Nucleic acid binding proteins

Info

Publication number
GB9710807D0
GB9710807D0 GBGB9710807.0A GB9710807A GB9710807D0 GB 9710807 D0 GB9710807 D0 GB 9710807D0 GB 9710807 A GB9710807 A GB 9710807A GB 9710807 D0 GB9710807 D0 GB 9710807D0
Authority
GB
United Kingdom
Prior art keywords
nucleic acid
binding proteins
acid binding
proteins
nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9710807.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Priority to GBGB9710807.0A priority Critical patent/GB9710807D0/en
Publication of GB9710807D0 publication Critical patent/GB9710807D0/en
Priority to AU75424/98A priority patent/AU7542498A/en
Priority to PCT/GB1998/001514 priority patent/WO1998053059A1/en
Pending legal-status Critical Current

Links

GBGB9710807.0A 1997-05-23 1997-05-23 Nucleic acid binding proteins Pending GB9710807D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9710807.0A GB9710807D0 (en) 1997-05-23 1997-05-23 Nucleic acid binding proteins
AU75424/98A AU7542498A (en) 1997-05-23 1998-05-26 Nucleic acid binding proteins
PCT/GB1998/001514 WO1998053059A1 (en) 1997-05-23 1998-05-26 Nucleic acid binding proteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9710807.0A GB9710807D0 (en) 1997-05-23 1997-05-23 Nucleic acid binding proteins

Publications (1)

Publication Number Publication Date
GB9710807D0 true GB9710807D0 (en) 1997-07-23

Family

ID=10813048

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9710807.0A Pending GB9710807D0 (en) 1997-05-23 1997-05-23 Nucleic acid binding proteins

Country Status (3)

Country Link
AU (1) AU7542498A (en)
GB (1) GB9710807D0 (en)
WO (1) WO1998053059A1 (en)

Families Citing this family (352)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
GB9824544D0 (en) * 1998-11-09 1999-01-06 Medical Res Council Screening system
US7262055B2 (en) 1998-08-25 2007-08-28 Gendaq Limited Regulated gene expression in plants
AU698152B2 (en) 1994-08-20 1998-10-22 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
CA2321938C (en) 1998-03-02 2009-11-24 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US6977154B1 (en) 1998-03-17 2005-12-20 Gendaq Limited Nucleic acid binding proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US7943731B1 (en) 1999-08-11 2011-05-17 Massachusetts Institute Of Technology Dimerizing peptides
IL150069A0 (en) 1999-12-06 2002-12-01 Sangamo Biosciences Inc Methods of using randomized libraries of zinc finger proteins for the identification of gene function
AU2693501A (en) 2000-01-24 2001-07-31 Gendaq Ltd Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
US7217509B2 (en) 2000-04-28 2007-05-15 Sangamo Biosciences, Inc. Databases of regulatory sequences; methods of making and using same
US6610489B2 (en) 2000-04-28 2003-08-26 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
US7923542B2 (en) 2000-04-28 2011-04-12 Sangamo Biosciences, Inc. Libraries of regulatory sequences, methods of making and using same
WO2001083819A2 (en) 2000-04-28 2001-11-08 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
AU2001252428A1 (en) * 2000-05-08 2001-11-20 Gendaq Limited Nucleic acid binding polypeptides
WO2002008286A2 (en) * 2000-07-21 2002-01-31 Syngenta Participations Ag Zinc finger domain recognition code and uses thereof
AU2001285252A1 (en) * 2000-08-25 2002-03-13 Gendaq, Ltd. Analysis of binding interactions
US6905816B2 (en) 2000-11-27 2005-06-14 Intelligent Medical Devices, Inc. Clinically intelligent diagnostic devices and methods
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US7273923B2 (en) 2001-01-22 2007-09-25 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
WO2002057308A2 (en) * 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
WO2003027247A2 (en) 2001-09-24 2003-04-03 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
CA2474486C (en) 2002-01-23 2013-05-14 The University Of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
EP1504108B1 (en) 2002-02-01 2013-04-17 Oxford Biomedica (UK) Limited Lentiviral vector
EP1527183B1 (en) 2002-07-26 2008-08-20 BASF Plant Science GmbH Novel selection method
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
AU2003298574B2 (en) 2002-09-05 2008-04-24 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
GB0228289D0 (en) 2002-12-04 2003-01-08 Genome Inst Of Singapore Nat U Method
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
ES2808687T3 (en) 2003-08-08 2021-03-01 Sangamo Therapeutics Inc Methods and compositions for directed cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US20120196370A1 (en) 2010-12-03 2012-08-02 Fyodor Urnov Methods and compositions for targeted genomic deletion
WO2005028630A2 (en) 2003-09-19 2005-03-31 Sangamo Biosciences, Inc. Engineered zinc finger proteins for regulation of gene expression
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005100393A1 (en) 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Methods and compositions for modulating cardiac contractility
US20050282193A1 (en) 2004-04-23 2005-12-22 Bulyk Martha L Space efficient polymer sets
US20060063231A1 (en) 2004-09-16 2006-03-23 Sangamo Biosciences, Inc. Compositions and methods for protein production
EP1869075B1 (en) 2005-02-28 2012-04-11 Sangamo BioSciences, Inc. Anti-angiogenic methods and compositions
JP2009502170A (en) 2005-07-26 2009-01-29 サンガモ バイオサイエンシズ インコーポレイテッド Targeted integration and expression of foreign nucleic acid sequences
JP5266210B2 (en) 2006-05-25 2013-08-21 サンガモ バイオサイエンシズ インコーポレイテッド Modified cleavage half-domain
EP2447279B1 (en) 2006-05-25 2014-04-09 Sangamo BioSciences, Inc. Methods and compositions for gene inactivation
US9428756B2 (en) 2006-08-11 2016-08-30 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
WO2008060510A2 (en) * 2006-11-13 2008-05-22 Sangamo Biosciences, Inc. Zinc finger nuclease for targeting the human glucocorticoid receptor locus
HUE029238T2 (en) 2006-12-14 2017-02-28 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
ATE489465T1 (en) 2007-04-26 2010-12-15 Sangamo Biosciences Inc TARGETED INTEGRATION INTO THE PPP1R12C POSITION
EP2171052B1 (en) 2007-07-12 2014-08-27 Sangamo BioSciences, Inc. Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2188384B1 (en) 2007-09-27 2015-07-15 Sangamo BioSciences, Inc. Rapid in vivo identification of biologically active nucleases
US20110014616A1 (en) 2009-06-30 2011-01-20 Sangamo Biosciences, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
WO2009042164A1 (en) 2007-09-27 2009-04-02 Dow Agrosciences Llc Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes
WO2009054985A1 (en) 2007-10-25 2009-04-30 Sangamo Biosciences, Inc. Methods and compositions for targeted integration
ES2459880T3 (en) 2008-04-14 2014-05-12 Sangamo Biosciences, Inc. Linear donor constructions for targeted integration
ES2551318T3 (en) 2008-04-21 2015-11-18 Danziger Innovations Ltd. Viral expression vectors of plants and their use to generate genotypic variations in plant genomes
KR101598867B1 (en) 2008-04-30 2016-03-03 산바이오 인코포레이티드 Neural regenerating cells with alterations in dna methylation
AU2009260888B2 (en) 2008-05-28 2014-09-11 Sangamo Therapeutics, Inc. Compositions for linking DNA-binding domains and cleavage domains
US8597912B2 (en) 2008-06-10 2013-12-03 Sangamo Biosciences, Inc. Methods and compositions for generation of Bax-and Bak-deficient cell lines
KR20160015400A (en) 2008-08-22 2016-02-12 상가모 바이오사이언스 인코포레이티드 Methods and compositions for targeted single-stranded cleavage and targeted integration
AU2009311697B2 (en) 2008-10-29 2014-12-18 Sangamo Therapeutics, Inc. Methods and compositions for inactivating glutamine synthetase gene expression
WO2010065123A1 (en) 2008-12-04 2010-06-10 Sangamo Biosciences, Inc. Genome editing in rats using zinc-finger nucleases
CA2747124C (en) 2008-12-17 2018-09-04 Dow Agrosciences Llc Targeted integration into the zp15 locus
JP5827132B2 (en) 2009-02-04 2015-12-02 サンガモ バイオサイエンシズ インコーポレイテッド Methods and compositions for treating neuropathy
EP2408921B1 (en) 2009-03-20 2017-04-19 Sangamo BioSciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
WO2010117464A1 (en) 2009-04-09 2010-10-14 Sangamo Biosciences, Inc. Targeted integration into stem cells
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
JP5866283B2 (en) 2009-07-28 2016-02-17 サンガモ バイオサイエンシーズ， インコーポレイテッド Methods and compositions for treating trinucleotide repeat disease
NZ598457A (en) 2009-08-03 2014-06-27 Recombinetics Inc Methods and compositions for targeted gene modification
KR102262704B1 (en) 2009-08-11 2021-06-09 상가모 테라퓨틱스, 인코포레이티드 Organisms homozygous for targeted modification
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
UA109418C2 (en) 2009-10-22 2015-08-25 Zinc Finger Protein Designed for Plant Genes Involved in Fatty Acid Biosynthesis
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
BR112012012588B1 (en) 2009-11-27 2019-03-26 Basf Plant Science Company Gmbh ENDONUCLEASE, METHOD FOR HOMOLOGICAL RECOMBINATION OF POLINUCLEOTIDES AND METHOD FOR DIRECTED POLINUCLEOTIDE MUTATION
WO2011090804A1 (en) 2010-01-22 2011-07-28 Dow Agrosciences Llc Targeted genomic alteration
WO2011097036A1 (en) 2010-02-08 2011-08-11 Sangamo Biosciences, Inc. Engineered cleavage half-domains
EP2534163B1 (en) 2010-02-09 2015-11-04 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
JP5952263B2 (en) 2010-04-26 2016-07-13 サンガモ バイオサイエンシーズ， インコーポレイテッド Genome editing of the ROSA locus using zinc finger nuclease
WO2011139349A1 (en) 2010-05-03 2011-11-10 Sangamo Biosciences, Inc. Compositions for linking zinc finger modules
CN103025344B (en) 2010-05-17 2016-06-29 桑格摩生物科学股份有限公司 Novel DNA-associated proteins and application thereof
JP6050230B2 (en) 2010-07-21 2016-12-21 サンガモ バイオサイエンシーズ， インコーポレイテッド Methods and compositions for modification of HLA loci
US9566352B2 (en) 2010-09-27 2017-02-14 Sangamo Biosciences, Inc. Methods and compositions for inhibiting viral entry into cells
ES2562421T3 (en) 2010-10-12 2016-03-04 The Children's Hospital Of Philadelphia Methods and compositions to treat hemophilia B
US9267123B2 (en) 2011-01-05 2016-02-23 Sangamo Biosciences, Inc. Methods and compositions for gene correction
EP2694554A1 (en) 2011-04-08 2014-02-12 Gilead Biologics, Inc. Methods and compositions for normalization of tumor vasculature by inhibition of loxl2
CA2841541C (en) 2011-07-25 2019-11-12 Sangamo Biosciences, Inc. Methods and compositions for alteration of a cystic fibrosis transmembrane conductance regulator (cftr) gene
SG10201811736QA (en) 2011-09-21 2019-02-27 Sangamo Therapeutics Inc Methods and compositions for regulation of transgene expression
WO2013063315A2 (en) 2011-10-27 2013-05-02 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
JP6144691B2 (en) 2011-11-16 2017-06-07 サンガモ セラピューティクス， インコーポレイテッド Modified DNA binding proteins and uses thereof
AU2013211934B2 (en) 2012-01-27 2017-09-14 Sanbio, Inc. Methods and compositions for modulating angiogenesis and vasculogenesis
EP2820159B1 (en) 2012-02-29 2019-10-23 Sangamo Therapeutics, Inc. Methods and compositions for treating huntington's disease
US20130280222A1 (en) 2012-04-18 2013-10-24 Board Of Regents Of The University Of Texas System Non-disruptive gene targeting
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
KR102091298B1 (en) 2012-05-02 2020-03-19 다우 아그로사이언시즈 엘엘씨 Targeted modification of malate dehydrogenase
JP6559063B2 (en) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for nuclease-mediated targeted integration of transgenes
WO2013169398A2 (en) 2012-05-09 2013-11-14 Georgia Tech Research Corporation Systems and methods for improving nuclease specificity and activity
EP3444342B1 (en) 2012-07-11 2020-05-27 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of lysosomal storage diseases
EP2872154B1 (en) 2012-07-11 2017-05-31 Sangamo BioSciences, Inc. Methods and compositions for delivery of biologics
US10648001B2 (en) 2012-07-11 2020-05-12 Sangamo Therapeutics, Inc. Method of treating mucopolysaccharidosis type I or II
KR102474010B1 (en) 2012-08-29 2022-12-02 상가모 테라퓨틱스, 인코포레이티드 Methods and compositions for treatment of a genetic condition
US9914930B2 (en) 2012-09-07 2018-03-13 Dow Agrosciences Llc FAD3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
UA119135C2 (en) 2012-09-07 2019-05-10 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Engineered transgene integration platform (etip) for gene targeting and trait stacking
UA118090C2 (en) 2012-09-07 2018-11-26 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Fad2 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks
JP6401704B2 (en) 2012-10-10 2018-10-10 サンガモ セラピューティクス， インコーポレイテッド Compounds that modify T cells and uses thereof
AU2013355327A1 (en) 2012-12-05 2015-06-11 Sangamo Therapeutics, Inc. Methods and compositions for regulation of metabolic disorders
RU2015128052A (en) 2012-12-13 2017-01-19 Дау Агросайенсиз Ллс PRECISE TARGETING OF GENES REGARDING SPECIFIC LOCUS OF CORN
JP6491113B2 (en) 2013-02-25 2019-03-27 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for enhancing nuclease-mediated gene disruption
CA2906970C (en) 2013-03-21 2021-05-18 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
EP2981166B1 (en) 2013-04-05 2020-09-09 Dow AgroSciences LLC Methods and compositions for integration of an exogenous sequence within the genome of plants
WO2014186435A2 (en) 2013-05-14 2014-11-20 University Of Georgia Research Foundation, Inc. Compositions and methods for reducing neointima formation
EP3730615A3 (en) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
JP6588438B2 (en) 2013-08-28 2019-10-09 サンガモ セラピューティクス， インコーポレイテッド Composition for linking a DNA binding domain and a cleavage domain
CA2926078C (en) 2013-10-17 2021-11-16 Sangamo Biosciences, Inc. Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells
CN105899665B (en) 2013-10-17 2019-10-22 桑格摩生物科学股份有限公司 The delivering method and composition being transformed for nuclease-mediated genome project
EP3066202B1 (en) 2013-11-04 2021-03-03 Dow AgroSciences LLC Optimal soybean loci
TWI659103B (en) 2013-11-04 2019-05-11 陶氏農業科學公司 Optimal soybean loci
EP3065540B1 (en) 2013-11-04 2021-12-15 Corteva Agriscience LLC Optimal maize loci
TWI721478B (en) 2013-11-04 2021-03-11 美商陶氏農業科學公司 Optimal maize loci
US10369201B2 (en) 2013-11-11 2019-08-06 Sangamo Therapeutics, Inc. Methods and compositions for treating Huntington's disease
SI3068881T1 (en) 2013-11-13 2019-05-31 Children's Medical Center Corporation Nuclease-mediated regulation of gene expression
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
JP6535684B2 (en) 2013-12-09 2019-06-26 サンガモ セラピューティクス， インコーポレイテッド Methods and compositions for genome manipulation
US10774338B2 (en) 2014-01-16 2020-09-15 The Regents Of The University Of California Generation of heritable chimeric plant traits
PL3102673T3 (en) 2014-02-03 2020-11-02 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a beta thalessemia
CA2939942A1 (en) 2014-02-24 2015-08-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration
TW201538518A (en) 2014-02-28 2015-10-16 Dow Agrosciences Llc Root specific expression conferred by chimeric gene regulatory elements
WO2015143046A2 (en) 2014-03-18 2015-09-24 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
CN106460009A (en) 2014-03-21 2017-02-22 小利兰·斯坦福大学托管委员会 Genome editing without nucleases
US10507232B2 (en) 2014-04-02 2019-12-17 University Of Florida Research Foundation, Incorporated Materials and methods for the treatment of latent viral infection
WO2015164748A1 (en) 2014-04-24 2015-10-29 Sangamo Biosciences, Inc. Engineered transcription activator like effector (tale) proteins
WO2015171932A1 (en) 2014-05-08 2015-11-12 Sangamo Biosciences, Inc. Methods and compositions for treating huntington's disease
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US10238581B2 (en) 2014-05-09 2019-03-26 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
WO2015175642A2 (en) 2014-05-13 2015-11-19 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a disease
US9970001B2 (en) 2014-06-05 2018-05-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease design
CA2954201A1 (en) 2014-07-08 2016-01-14 Vib Vzw Means and methods to increase plant yield
EP3169778B1 (en) 2014-07-14 2023-10-25 Washington State University Nanos knock-out that ablates germline cells
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US11278572B2 (en) 2014-07-18 2022-03-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
US9757420B2 (en) 2014-07-25 2017-09-12 Sangamo Therapeutics, Inc. Gene editing for HIV gene therapy
WO2016019144A2 (en) 2014-07-30 2016-02-04 Sangamo Biosciences, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
EP3878948A1 (en) 2014-09-16 2021-09-15 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
US10889834B2 (en) 2014-12-15 2021-01-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing targeted transgene integration
EP3247366A4 (en) 2015-01-21 2018-10-31 Sangamo Therapeutics, Inc. Methods and compositions for identification of highly specific nucleases
SG11201706041XA (en) 2015-01-26 2017-08-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
WO2016161446A1 (en) 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
CA2982927C (en) 2015-04-15 2023-08-29 Dow Agrosciences Llc Plant promoter for transgene expression
AU2016250064A1 (en) 2015-04-15 2017-10-19 Dow Agrosciences Llc Plant promoter for transgene expression
US11845928B2 (en) 2015-05-04 2023-12-19 Tsinghua University Methods and kits for fragmenting DNA
US10179918B2 (en) 2015-05-07 2019-01-15 Sangamo Therapeutics, Inc. Methods and compositions for increasing transgene activity
SG10202112057QA (en) 2015-05-12 2021-12-30 Sangamo Therapeutics Inc Nuclease-mediated regulation of gene expression
MX2017015239A (en) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composition and methods for regulating inhibitory interactions in genetically engineered cells.
US9957501B2 (en) 2015-06-18 2018-05-01 Sangamo Therapeutics, Inc. Nuclease-mediated regulation of gene expression
CA2991301A1 (en) 2015-07-13 2017-01-19 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
EP4361279A2 (en) 2015-08-06 2024-05-01 The Curators of the University of Missouri Pathogen-resistant animals having modified cd163 genes
TW201718862A (en) 2015-09-22 2017-06-01 Dow Agrosciences Llc Plant promoter and 3' UTR for transgene expression
TW201718861A (en) 2015-09-22 2017-06-01 道禮責任有限公司 Plant promoter and 3'UTR for transgene expression
EP3352776A4 (en) 2015-09-23 2019-03-13 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
EP3365451B1 (en) 2015-10-22 2020-06-24 Dow Agrosciences LLC Plant promoter for transgene expression
WO2017078935A1 (en) 2015-11-04 2017-05-11 Dow Agrosciences Llc Plant promoter for transgene expression
JP2018533363A (en) 2015-11-04 2018-11-15 フェイト セラピューティクス，インコーポレイテッド Methods and compositions for inducing hematopoietic cell differentiation
ES2953925T3 (en) 2015-11-04 2023-11-17 Fate Therapeutics Inc Genomic engineering of pluripotent cells
CA3004349A1 (en) 2015-11-23 2017-06-01 Sangamo Therapeutics, Inc. Methods and compositions for engineering immunity
US11352631B2 (en) 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
IL297018A (en) 2015-12-18 2022-12-01 Sangamo Therapeutics Inc Targeted disruption of the mhc cell receptor
SG11201805680SA (en) 2016-01-15 2018-07-30 Sangamo Therapeutics Inc Methods and compositions for the treatment of neurologic disease
JP7012650B2 (en) 2016-02-02 2022-01-28 サンガモ セラピューティクス， インコーポレイテッド Composition for linking DNA binding domain and cleavage domain
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
JP2019508037A (en) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ Compositions for enhancing targeted gene editing and methods of use thereof
WO2017165655A1 (en) 2016-03-23 2017-09-28 Dana-Farber Cancer Institute, Inc. Methods for enhancing the efficiency of gene editing
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3448997B1 (en) 2016-04-27 2020-10-14 Massachusetts Institute of Technology Stable nanoscale nucleic acid assemblies and methods thereof
US11514331B2 (en) 2016-04-27 2022-11-29 Massachusetts Institute Of Technology Sequence-controlled polymer random access memory storage
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
WO2018013840A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
CA3031818A1 (en) 2016-07-27 2018-02-01 Case Western Reserve University Compounds and methods of promoting myelination
US11193136B2 (en) 2016-08-09 2021-12-07 Vib Vzw Cellulose synthase inhibitors and mutant plants
BR112019003327A2 (en) 2016-08-24 2019-07-02 Sangamo Therapeutics Inc specific target engineered nucleases
IL264639B2 (en) 2016-08-24 2024-01-01 Sangamo Therapeutics Inc Regulation of globulin gene expression using engineered zinc finger nucleases
US10960085B2 (en) 2016-09-07 2021-03-30 Sangamo Therapeutics, Inc. Modulation of liver genes
EP3519433A1 (en) 2016-10-03 2019-08-07 Juno Therapeutics, Inc. Hpv-specific binding molecules
BR112019005687A2 (en) 2016-10-03 2019-07-02 Dow Agrosciences Llc plant promoter for transgenic expression
US10400246B2 (en) 2016-10-03 2019-09-03 Dow Agrosciences Llc Plant promoter for transgene expression
WO2018067826A1 (en) 2016-10-05 2018-04-12 Cellular Dynamics International, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
MA46649A (en) 2016-10-13 2019-08-21 Juno Therapeutics Inc METHODS AND COMPOSITIONS OF IMMUNOTHERAPY INVOLVING MODULATORS OF THE TRYPTOPHAN METABOLIC PATHWAY
CN110022904B (en) 2016-10-20 2024-04-19 桑格摩生物治疗股份有限公司 Methods and compositions for treating brile disease
WO2018081138A1 (en) 2016-10-24 2018-05-03 Yale University Biodegradable contraceptive implants
AU2017347928A1 (en) 2016-10-31 2019-05-09 Sangamo Therapeutics, Inc. Gene correction of scid-related genes in hematopoietic stem and progenitor cells
AU2017367722B2 (en) 2016-12-01 2024-02-01 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
CN110494565A (en) 2016-12-02 2019-11-22 朱诺治疗学股份有限公司 It is engineered B cell and compositions related and method
US20190350978A1 (en) 2016-12-05 2019-11-21 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
CA3046199A1 (en) 2016-12-08 2018-06-14 Case Western Reserve University Methods and compositions for enhancing functional myelin production
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
JP2020508056A (en) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ Compositions and methods for gene editing
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
SG11201906948UA (en) 2017-04-20 2019-08-27 Univ Oregon Health & Science Human gene correction
AU2018261366A1 (en) 2017-05-03 2019-10-31 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CTFR) gene
US11512287B2 (en) 2017-06-16 2022-11-29 Sangamo Therapeutics, Inc. Targeted disruption of T cell and/or HLA receptors
SG11202002728VA (en) 2017-10-03 2020-04-29 Juno Therapeutics Inc Hpv-specific binding molecules
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
SG11202004003YA (en) 2017-11-09 2020-05-28 Sangamo Therapeutics Inc Genetic modification of cytokine inducible sh2-containing protein (cish) gene
US10940171B2 (en) 2017-11-10 2021-03-09 Massachusetts Institute Of Technology Microbial production of pure single stranded nucleic acids
WO2019100053A1 (en) 2017-11-20 2019-05-23 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating hif-2α to improve muscle generation and repair
EP3728563A4 (en) 2017-12-22 2021-11-10 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof
WO2019143675A1 (en) 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
KR20200110687A (en) 2018-01-17 2020-09-24 버텍스 파마슈티칼스 인코포레이티드 Quinoxalinone compounds, compositions, methods and kits for increasing genome editing efficiency
IL276080B2 (en) 2018-01-17 2023-10-01 Vertex Pharma Dna-pk inhibitor compounds, compositions comprising same and uses thereof
AU2019218118A1 (en) 2018-02-08 2020-08-13 Sangamo Therapeutics, Inc. Engineered target specific nucleases
AU2019243315A1 (en) 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
EP3775238A1 (en) 2018-04-05 2021-02-17 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
CA3095084A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
PE20201345A1 (en) 2018-04-05 2020-11-25 Juno Therapeutics Inc RECEIVERS OF T-CELLS, AND DESIGNED CELLS THAT EXPRESS THEM
CN112313246A (en) 2018-04-18 2021-02-02 桑格摩生物治疗股份有限公司 Zinc finger protein compositions for modulating Huntingtin (HTT)
EP3790629A1 (en) 2018-05-11 2021-03-17 CRISPR Therapeutics AG Methods and compositions for treating cancer
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
GB201809273D0 (en) 2018-06-06 2018-07-25 Vib Vzw Novel mutant plant cinnamoyl-coa reductase proteins
EP3802839A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Nucleic acid constructs and methods of using same
WO2019234750A1 (en) 2018-06-07 2019-12-12 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of regenerating and transforming cannabis
WO2020028617A1 (en) 2018-08-01 2020-02-06 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development
CA3109592A1 (en) 2018-08-23 2020-02-27 Sangamo Therapeutics, Inc. Engineered target specific base editors
KR20210054547A (en) 2018-08-31 2021-05-13 예일 유니버시티 Compositions and methods for enhancing triplex and nuclease based gene editing
CN113015741A (en) 2018-09-18 2021-06-22 桑格摩生物治疗股份有限公司 Programmed cell death 1(PD1) specific nucleases
KR20210089707A (en) 2018-11-07 2021-07-16 크리스퍼 테라퓨틱스 아게 Anti-LIV1 Immune Cell Cancer Therapy
KR20210092236A (en) 2018-11-07 2021-07-23 크리스퍼 테라퓨틱스 아게 Anti-PTK7 immune cell cancer therapy
MX2021005398A (en) 2018-11-07 2021-07-06 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy.
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
CA3121781A1 (en) 2018-12-05 2020-06-11 Vertex Pharmaceuticals Incorporated Gene-editing systems for editing a cystic fibrosis transmembrane regulator (cftr) gene
GB201820109D0 (en) 2018-12-11 2019-01-23 Vib Vzw Plants with a lignin trait and udp-glycosyltransferase mutation
AU2020205717A1 (en) 2019-01-11 2021-08-12 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
WO2020154595A1 (en) 2019-01-24 2020-07-30 Massachusetts Institute Of Technology Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom
CN112805026A (en) 2019-02-06 2021-05-14 桑格摩生物治疗股份有限公司 Methods for treating mucopolysaccharidosis type I
SG11202109225WA (en) 2019-03-08 2021-09-29 Obsidian Therapeutics Inc Cd40l compositions and methods for tunable regulation
SG11202110776TA (en) 2019-04-02 2021-10-28 Sangamo Therapeutics Inc Methods for the treatment of beta-thalassemia
TW202104249A (en) 2019-04-23 2021-02-01 美商聖加莫治療股份有限公司 Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
BR112021021075A2 (en) 2019-05-01 2021-12-14 Editas Medicine Inc Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
BR112021021200A2 (en) 2019-05-01 2021-12-21 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides, and methods
US11905532B2 (en) 2019-06-25 2024-02-20 Massachusetts Institute Of Technology Compositions and methods for molecular memory storage and retrieval
CN114269372A (en) 2019-06-27 2022-04-01 克里斯珀医疗股份公司 Use of chimeric antigen receptor T cells and NK cell inhibitors for the treatment of cancer
US20220267732A1 (en) 2019-08-01 2022-08-25 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
EP4017508A1 (en) 2019-08-23 2022-06-29 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
CN115151275A (en) 2019-08-30 2022-10-04 耶鲁大学 Compositions and methods for delivering nucleic acids to cells
CN114729325A (en) 2019-09-06 2022-07-08 克里斯珀医疗股份公司 Genetically engineered T cells with improved persistence in culture
EP4041754A1 (en) 2019-10-02 2022-08-17 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing alpha-synuclein expression
US20230002459A1 (en) 2019-10-02 2023-01-05 Sangamo Therapeutics, Inc. Zinc Finger Protein Transcription Factors for Treatment of Prion Disease
EP4051787A1 (en) 2019-11-01 2022-09-07 Sangamo Therapeutics, Inc. Gin recombinase variants
EP4051322A1 (en) 2019-11-01 2022-09-07 Sangamo Therapeutics, Inc. Compositions and methods for genome engineering
US20230056856A1 (en) 2020-01-08 2023-02-23 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
AU2021209699A1 (en) 2020-01-22 2022-07-21 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing tau expression
WO2021155065A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
MX2022011831A (en) 2020-03-25 2023-01-04 Sana Biotechnology Inc Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions.
AU2021268253A1 (en) 2020-05-06 2022-12-08 Cellectis S.A. Methods for targeted insertion of exogenous sequences in cellular genomes
JP2023525510A (en) 2020-05-06 2023-06-16 セレクティス ソシエテ アノニム Methods of genetically modifying cells for delivery of therapeutic proteins
KR20230022868A (en) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 Method for producing donor-batch cells expressing a recombinant acceptor
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
AU2021308681A1 (en) 2020-07-16 2023-03-09 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022036150A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
US20220064596A1 (en) 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
EP4204002A1 (en) 2020-08-31 2023-07-05 Yale University Compositions and methods for delivery of nucleic acids to cells
CN116322716A (en) 2020-09-23 2023-06-23 克里斯珀医疗股份公司 Genetically engineered T cells disrupted by Regnase-1 and/or TGFBRII have improved functionality and persistence
CN116261594A (en) 2020-09-25 2023-06-13 桑格摩生物治疗股份有限公司 Zinc finger fusion proteins for nucleobase editing
CA3197644A1 (en) 2020-10-02 2022-04-07 Sangamo Therapeutics, Inc. Novel zinc finger protein transcription factors for repressing alpha-synuclein expression
US20230398148A1 (en) 2020-11-04 2023-12-14 Juno Therapeutics, Inc. Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
EP4243609A1 (en) 2020-11-16 2023-09-20 Pig Improvement Company UK Limited Influenza a-resistant animals having edited anp32 genes
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2023553419A (en) 2020-12-03 2023-12-21 センチュリー セラピューティクス，インコーポレイテッド Genetically engineered cells and their uses
US20220193134A1 (en) 2020-12-23 2022-06-23 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
JP2024501971A (en) 2020-12-31 2024-01-17 サナ バイオテクノロジー，インコーポレイテッド Methods and compositions for modulating CAR-T activity
AU2022207981A1 (en) 2021-01-12 2023-07-27 March Therapeutics, Inc. Context-dependent, double-stranded dna-specific deaminases and uses thereof
EP4305153A1 (en) 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
WO2022204071A1 (en) 2021-03-22 2022-09-29 Juno Therapeutics, Inc. Method to assess potency of viral vector particles
BR112023018844A2 (en) 2021-04-07 2023-10-10 Century Therapeutics Inc COMPOSITIONS AND METHODS FOR GENERATION OF GAMMA-DELTA T CELLS FROM INDUCED PLURIPOTENT STEM CELLS
CN117479952A (en) 2021-04-07 2024-01-30 世纪治疗股份有限公司 Combined artificial cell death/reporter polypeptides for chimeric antigen receptor cells and uses thereof
CA3214473A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
CA3217672A1 (en) 2021-05-05 2022-11-10 FUJIFILM Cellular Dynamics, Inc. Methods and compositions for ipsc-derived microglia
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2022251367A1 (en) 2021-05-27 2022-12-01 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (en) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. Altered expression of Y chromosome-linked antigens in hypoimmunogenic cells
AU2022318664A1 (en) 2021-07-30 2024-02-29 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
WO2023010133A2 (en) 2021-07-30 2023-02-02 Tune Therapeutics, Inc. Compositions and methods for modulating expression of frataxin (fxn)
AU2022325955A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
AU2022325231A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
CA3227108A1 (en) 2021-08-11 2023-02-16 Xiaomeng HU Genetically modified primary cells for allogeneic cell therapy
KR20240053673A (en) 2021-08-11 2024-04-24 사나 바이오테크놀로지, 인크. Inducible system for altering gene expression in hypoimmunogenic cells
AU2022326565A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
KR20240055838A (en) 2021-09-10 2024-04-29 후지필름 셀룰러 다이내믹스, 인코포레이티드 Compositions of cells derived from induced pluripotent stem cells and methods of using the same
WO2023042079A1 (en) 2021-09-14 2023-03-23 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
WO2023070043A1 (en) 2021-10-20 2023-04-27 Yale University Compositions and methods for targeted editing and evolution of repetitive genetic elements
AU2022371442A1 (en) 2021-10-21 2024-04-18 Vertex Pharmaceuticals Incorporated Hypoimmune cells
WO2023069790A1 (en) 2021-10-22 2023-04-27 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
CA3235390A1 (en) 2021-10-29 2023-05-04 Deepika Rajesh Dopaminergic neurons comprising mutations and methods of use thereof
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023111913A1 (en) 2021-12-15 2023-06-22 Crispr Therapeutics Ag Engineered anti-liv1 cell with regnase-1 and/or tgfbrii disruption
US20230346836A1 (en) 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2023122722A1 (en) 2021-12-22 2023-06-29 Sangamo Therapeutics, Inc. Novel zinc finger fusion proteins for nucleobase editing
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
WO2023129937A1 (en) 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
WO2023131616A1 (en) 2022-01-05 2023-07-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
WO2023137472A2 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
TW202340457A (en) 2022-02-28 2023-10-16 美商凱特製藥公司 Allogeneic therapeutic cells
US20230279376A1 (en) 2022-03-01 2023-09-07 Crispr Therapeutics Ag Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023180904A1 (en) 2022-03-21 2023-09-28 Crispr Therapeutics Ag Methods and compositions for treating lipoprotein-related diseases
WO2023180967A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd83 car-t cells with regnase-1 and/or tgfbrii disruption
WO2023180968A1 (en) 2022-03-23 2023-09-28 Crispr Therapeutics Ag Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof
WO2023192872A1 (en) 2022-03-28 2023-10-05 Massachusetts Institute Of Technology Rna scaffolded wireframe origami and methods thereof
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
WO2023240169A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
WO2023240212A2 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof
WO2023242827A2 (en) 2022-06-17 2023-12-21 Crispr Therapeutics Ag LIPID NANOPARTICLES (LNPs)-BASED OCULAR DELIVERY
WO2023248145A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Compositions and methods for treating human immunodeficiency virus
WO2023248147A1 (en) 2022-06-21 2023-12-28 Crispr Therapeutics Ag Methods and compositions for in vivo editing of stem cells
WO2023250511A2 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
WO2024003786A1 (en) 2022-06-29 2024-01-04 Crispr Therapeutics Ag Chimeric antigen receptor targeting gpc-3 and immune cells expressing such for therapeutic uses
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof
WO2024015881A2 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. Compositions, systems, and methods for targeted transcriptional activation
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
WO2024020597A1 (en) 2022-07-22 2024-01-25 The Johns Hopkins University Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024040254A2 (en) 2022-08-19 2024-02-22 Tune Therapeutics, Inc. Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
WO2024064642A2 (en) 2022-09-19 2024-03-28 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
WO2024062388A2 (en) 2022-09-20 2024-03-28 Crispr Therapeutics Ag Genetically engineered immune cells expressing chimeric antigen receptor targeting cd20
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies
WO2024102838A1 (en) 2022-11-09 2024-05-16 Century Therapeutics, Inc. Engineered interleukin-7 receptors and uses thereof
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024103017A2 (en) 2022-11-10 2024-05-16 Century Therapeutics, Inc. Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698152B2 (en) * 1994-08-20 1998-10-22 Gendaq Limited Improvements in or relating to binding proteins for recognition of DNA

Also Published As

Publication number Publication date
WO1998053059A1 (en) 1998-11-26
AU7542498A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
GB9710807D0 (en) Nucleic acid binding proteins
GB9620769D0 (en) Nucleic acid sequencing
IL131648A0 (en) Nucleic acid indexing
IL130886A0 (en) Nucleic acid sequencing
IL136988A0 (en) Novel nucleic acid and polypeptide
ZA984322B (en) Sucrose-binding proteins
AU6376698A (en) Improved nucleic acid assays
EP0885238A4 (en) Substituted nucleic acid mimics
AU1320600A (en) Human rna binding proteins
GB9710811D0 (en) Nucleic acid binding proteins
GB9710805D0 (en) Nucleic acid binding proteins
GB9710806D0 (en) Nucleic acid binding proteins
GB9710812D0 (en) Nucleic acid binding proteins
GB9710808D0 (en) Nucleic acid binding proteins
GB9710810D0 (en) Nucleic acid binding proteins
GB9811307D0 (en) Nucleic acid binding proteins
GB9811261D0 (en) Nucleic acid binding proteins
GB9807246D0 (en) Nucleic acid binding proteins
GB9806895D0 (en) Nucleic acid binding proteins
EP1012160A4 (en) Tango-72 and tango-77 nucleic acid molecules and polypeptides
EP1026245A4 (en) Antigen protein and nucleic acid coding for said protein
GB9725630D0 (en) Charecterising nucleic acid
GB9701887D0 (en) Nucleic acid
GB9701886D0 (en) Nucleic acid
IL120283A0 (en) Nucleic acid sequences and proteins